ArticleThe Prostate2010
Association of hepsin gene variants with prostate cancer risk and prognosis.
Article in The Prostate, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Machine learning models for predicting prostate cancer recurrence and identifying potential molecular biomarkers.Frontiers in oncology · 2025Article
- Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer.Biomolecules · 2022Review
- Hepsin Promotes Epithelial-Mesenchymal Transition and Cell Invasion Through the miR-222/PPP2R2A/AKT Axis in Prostate Cancer.OncoTargets and therapy · 2020Article
- Cell surface-anchored serine proteases in cancer progression and metastasis.Cancer metastasis reviews · 2019Review
- Hybrid Method Based on Information Gain and Support Vector Machine for Gene Selection in Cancer Classification.Genomics, proteomics & bioinformatics · 2017Article
- Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.EBioMedicine · 2015Article
- Cell type specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity.Oncotarget · 2015Article
- The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Frontiers in oncology · 2014Review
- Article
- HEV-ORF3 Encoding Phosphoprotein Interacts With Hepsin.Hepatitis monthly · 2014Article
- Article
- Variants in the HEPSIN gene are associated with susceptibility to prostate cancer.Prostate cancer and prostatic diseases · 2012Article
- Regulators of gene expression as biomarkers for prostate cancer.American journal of cancer research · 2012Article
- Biomarkers in prostate cancer epidemiology.Cancers · 2011Article
- Vitamin D pathway gene variants and prostate cancer prognosis.The Prostate · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundHepsin (HPN) is one of the most consistently overexpressed genes in prostate cancer and there is some evidence supporting an association between HPN gene variants and prostate cancer risk. We report results from a population-based case-control genetic association study for six tagging single nucleotide polymorphisms (tagSNPs) in the HPN gene.
methodsProstate cancer risk was estimated using adjusted unconditional logistic regression in 1,401 incident prostate cancer cases diagnosed in 1993 through 1996 or 2002 through 2005 and 1,351 age-matched controls. Risks of disease recurrence/progression and prostate cancer-specific mortality were estimated using Cox proportional hazards (PH) regression in 437 cases with long-term follow-up.
resultsThere were 135 recurrence/progression events and 57 cases who died of prostate cancer. Contrary to some earlier studies, we found no evidence of altered risk of developing prostate cancer overall or when clinical measures of tumor aggressiveness were considered for any of the tagSNPs, assessed either individually or by haplotypes. There was no evidence of altered risks of tumor recurrence/progression or prostate cancer death associated with variants in the HPN gene.
conclusionsGermline genetic variation of HPN does not seem to contribute to risk of prostate cancer or prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.